Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.55 |
| ▸ | SLC22A12 | Q96S37 | 12/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.49 |
| ▸ | EYA3 | Q99504 | 4/20 | 0.49 |
| ▸ | TTR | P02766 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | EYA2 | O00167 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.49 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALB | P02768 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22658406 | 0.87 | CYP2C19 (0.51) | CYP2C19SLC22A12NR1H4EYA3TTR | |
| Benzbromarone SCHEMBL22658405 | 0.84 | SLC22A12 (0.67) | CYP2C19SLC22A12NR1H4EYA3TTR | |
| SCHEMBL25815022 | 0.83 | CYP2C19 (0.79) | CYP2C19SLC22A12NR1H4EYA3TTR | |
| SCHEMBL25815054 | 0.82 | SLC22A12 (0.67) | CYP2C19SLC22A12NR1H4EYA3TTR | |
| SCHEMBL26211986 | 0.76 | SLC22A12 (0.54) | CYP2C19SLC22A12NR1H4EYA3TTR | |
| Benzarone SCHEMBL22658418 | 0.75 | SLC22A12 (0.67) | CYP2C19SLC22A12NR1H4EYA3TTR | |
| SCHEMBL24221837 | 0.75 | CYP2C19 (0.47) | CYP2C19SLC22A12NR1H4EYA3TTR | |
| SCHEMBL22658409 | 0.75 | SLC22A12 (0.61) | CYP2C19SLC22A12NR1H4EYA3CYP2C9 | |
| SCHEMBL24102976 | 0.74 | CYP2C19 (0.46) | CYP2C19SLC22A12NR1H4EYA3TTR | |
| SCHEMBL22072519 | 0.74 | TTR (0.46) | CYP2C19SLC22A12NR1H4EYA3TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419854-B2 | Methods for treating or preventing gout or hyperuricemia | ARTHROSI THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250066316-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | SHANGHAI STA PHARMACEUTICAL R&D CO., LTD. (CN) | 2025-02-27 | — | — | US | disclosed |
| US-20250059150-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS INC (US) | 2025-02-20 | — | — | US | disclosed |
| US-12145917-B2 | Crystalline forms of a compound for treating or preventing gout or hyperuricemia | ARTHROSI THERAPEUTICS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20230218563-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ARTHROSI THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| EP-4164624-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | Arthrosi Therapeutics, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20220242841-A1 | COMPOUND FOR TREATING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2022-08-04 | — | — | US | disclosed |
| EP-3968989-A1 | COMPOUND FOR TREATING GOUT OR HYPERURICEMIA | Arthrosi Therapeutics, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220023251-A1 | METHODS FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220024889-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2022-01-27 | — | — | US | disclosed |
| WO-2021252630-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ARTHROSI THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2020232156-A1 | COMPOUND FOR TREATING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419854-B2 | Methods for treating or preventing gout or hyperuricemia | CYP27B1, XDH, CYP27A1 | CYP2C19 660/4885SLC22A12 830/4885NR1H4 255/4885 |
| US-20220024889-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | CYP27A1, CYP24A1, CYP27B1 | CYP2C19 649/4885SLC22A12 854/4885NR1H4 97/4885 |
| US-20220023251-A1 | METHODS FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | CYP27B1, XDH, CYP27A1 | CYP2C19 660/4885SLC22A12 830/4885NR1H4 255/4885 |
| US-20220242841-A1 | COMPOUND FOR TREATING GOUT OR HYPERURICEMIA | CYP27A1, CYP27B1, XDH | CYP2C19 824/4885SLC22A12 564/4885NR1H4 67/4885 |
| US-20250066316-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | CYP27A1, CYP24A1, CYP27B1 | CYP2C19 649/4885SLC22A12 854/4885NR1H4 97/4885 |
| US-12145917-B2 | Crystalline forms of a compound for treating or preventing gout or hyperuricemia | CYP27A1, CYP24A1, CYP27B1 | CYP2C19 649/4885SLC22A12 854/4885NR1H4 97/4885 |
| US-20250059150-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | CYP27A1, CYP24A1, CYP27B1 | CYP2C19 649/4885SLC22A12 854/4885NR1H4 97/4885 |
| US-20230218563-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ATP6V1B1, REN, CYP27B1 | CYP2C19 826/4885SLC22A12 620/4885NR1H4 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.